This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


trusted source


Clinical trial generates promising results for obinutuzumab in patients with lupus nephritis

Credit: Pixabay/CC0 Public Domain

In a post hoc analysis of the Phase II NOBILITY trial, researchers found that treatment with obinutuzumab—an antibody that targets a protein expressed on certain immune cells—was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis, a kidney condition associated with the autoimmune disease lupus.

In the analysis, which is published in Arthritis & Rheumatology, compared with standard-of-care treatment alone, the addition of obinutuzumab to lupus nephritis treatment reduced the risk of developing a composite outcome of death, fall in kidney function, or treatment failure by 60%.

Adding obinutuzumab also reduced the risk of lupus nephritis relapses by 57% and significantly decreased the rate of decline in over the two years of the trial.

Overall, 38% of obinutuzumab-treated compared with 16% of placebo-treated patients achieved a complete remission of lupus nephritis by week 76, with the need for fewer glucocorticoids.

"These data are really important because the ultimate goal of lupus nephritis therapy is to preserve kidney survival so patients never have to face the need for dialysis or transplantation because their kidneys failed," said corresponding author Brad Rovin, MD, of Ohio State University Wexner Medical Center. "The addition of obinutuzumab to standard therapy may increase the likelihood of achieving this goal."

More information: Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients with Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial, Arthritis & Rheumatology (2023). DOI: 10.1002/art.42734. acrjournals.onlinelibrary.wile … com/journal/23265205

Provided by Wiley
Citation: Clinical trial generates promising results for obinutuzumab in patients with lupus nephritis (2023, November 10) retrieved 21 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Voclosporin safe, effective for long-term treatment of lupus nephritis


Feedback to editors